This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

ABX-10241

Amgen, Inc.

Drug Names(s): ABX-PTH

Description: ABX-PTH is a fully human monoclonal antibody that inhibits parathyroid hormone (PTH) activity. In preclinical studies, such inhibition leads to diminished PTH secretion. Elevated PTH, in all of its forms, is associated with bone pain, fractures, and increased mortality. Current therapy for both primary and secondary hyperparathyroidism includes vitamin D analog supplements, calcium supplements, bisphosphonates, calcitonin and calcitonin analogs, phosphate restriction and phosphate binding resins, estrogens, dialysis, and surgery. Such therapies still leave patients with unacceptable complications, morbidity, and mortality.

Amgen’s Cinacalcet, a second-generation calcimimetic, is approaching approval for the treatment of secondary hyperparathyroidism. Cinacalcet has demonstrated a bona fide potential to impact aspects of the fundamental biochemistry of hypercalcemia due to hyperparathyroidism without specific attendant calcium balance-related adversities associated with contemporary therapy.

Although anti-PTH antibodies have been developed with a great deal of success in the diagnostic imaging arena, their development as therapeutics has been slow because of the complex, downstream effects of direct PTH inhibition. The preclinical literature relating to the potential therapeutic use of parathyroid hormone related protein (PTHrp) inhibition is richer than that associated with direct PTH inhibition.

Deal Structure: Amgen completed its acquisition of Abgenix in April, 2006. Amgen acquired Abgenix for a total cash consideration of approximately $2.2 billion plus assumed debt. Amgen paid stockholders of Abgenix $22.50 in cash per share of common stock held at the closing.


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug